Cabazitaxel after docetaxel: A new option in metastatic castration-resistant prostate cancer;Cabazitaxel après docétaxel, une nouvelle option dans le cancer métastatique de la prostate résistant à la castration

Bulletin du Cancer

Volumn 99, Issue 9, 2012, Pages 875-880

  Lheureux, Stéphanie ^a   Joly, Florence ^a,b  

^a Francois Baclesse Anticancer Center   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Cabazitaxel; Metastatic castration resistant prostate cancer

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; DOCETAXEL; HEMOPOIETIC GROWTH FACTOR; PREDNISONE;

CANCER CHEMOTHERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; FEBRILE NEUTROPENIA; HUMAN; METASTASIS; OVERALL SURVIVAL; REVIEW; TREATMENT RESPONSE;

EID: 84867121860     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1617     Document Type: Article

References (20)

1. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14 : 1756-64. (Pubitemid 26185452)
2. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17 : 2506-13. (Pubitemid 29368252)
3. Tannock IF, de WR, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 : 1502-12.
4. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 : 1995-2005.
5. Bissery MC, Bouchard H, Riou JF, et al. Preclinical evaluation of TXD258, a new taxoid. Proceedings of the 91st American Association for Cancer Research. 2000; 41 : 214.
6. Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 2003; 138 : 1367-75. (Pubitemid 36543135)
7. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15 : 723-30.
8. Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19 : 1547-52.
9. Shigeta K, Miura Y, Naito Y, Takano T. Cabazitaxel for castration-resistant prostate cancer. Lancet 2011; 377 : 121-3.
10. Froehner M, Wirth MP. Cabazitaxel for castration-resistant prostate cancer. Lancet 2011; 377 : 121-2.
11. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376 : 1147-54.
12. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24 : 3187-205. (Pubitemid 46638957)
13. Dorff TB, Quinn DI. Cabazitaxel in prostate cancer: stretching a string. Lancet 2010; 376 : 1119-20.
14. Villanueva C, Bazan F, Kim S, et al. Cabazitaxel: a novel microtubule inhibitor. Drugs 2011; 71 : 1251-8.
15. Masson S, Bahl A. Metastatic castrate-resistant prostate cancer: dawn of a new age of management. BJU Int 2012 (PMID : 22564337).
16. Beuzeboc P, Ropert S, Goldwasser F, Zerbib M. Management of metastatic castration-resistant prostate cancer following docetaxel. Bull Cancer 2012 (PMID : 22516457).
17. Albiges L, Loriot Y, Gross-Goupil M, et al. New drugs in metastatic castration-resistant prostate cancer. Bull Cancer 2010; 97 : 149-59.
18. Scher H, Fizazi K, Saad F, et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol 2012 ; 30 (suppl. 5 ; abstr LBA1).
19. Sartor A, Heinrich D, O'Sullivan J, et al. Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: interim results of a phase III trial (ALSYMPCA). J Clin Oncol 2012 ; 30 (suppl ; abstr 4551).
20. Armstrong AJ, Eisenberger MA, Halabi S, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 2012; 61 : 549-59.